123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)

BACKGROUND: Candida species are a major cause of invasive and mucocutaneouls infections. There are limited oral treatment options available for patients with Candida infections who are unresponsive to or who are intolerant of currently available antifungals. Oral ibrexafungerp is an investigational...

Descripción completa

Detalles Bibliográficos
Autores principales: Pappas, Peter G, Cornely, Oliver, Koehler, Philipp, McCarty, Todd P, Alexander, Barbara D, Miller, Rachel, Vazquez, Jose A, Sanders, John W, Morse, Caryn, Ostrosky-Zeichner, Luis, Krause, Robert, Prattes, Jürgen, Spec, Andrej, Rautemaa-Richardson, Riina, Bazaz, Rohit, Walsh, Thomas J, Marty, Francisco M, Gonzalez-Bocco, Isabel H, Miceli, Marisa, Hoenigl, Martin, Patterson, Thomas F, Azie, Nkechi, Angulo, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644751/
http://dx.doi.org/10.1093/ofid/ofab466.123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644751/
http://dx.doi.org/10.1093/ofid/ofab466.123

Ejemplares similares